Dow Chemical, 1978.

34. Pirkle JL, Wolfe WH, Patterson DG, Needham LL, Michalek, JE, Miner JC, Peterson MR, Phillips DL. Estimates of the half life of 2,3,7,8 tetrachlorodibenzo-p-dioxin in Vietnam veterans of Operation Ranch Hand. J Toxicol Environ Health 1989; 27(2)165-71.

35. Butler MG. Acneiform dermatosis produced by ortho (2 chlorophenyl) phenol sodium and tetrachlorophenol sodium. Arch Derm Syph 1937; 35:252-254.

36. Stingily KO. A new industrial chemical dermatitis. Southern Medical J 1940; 33:1268-1272.

37. Moses M, Lilis R, Thornton J, Fischbein A, Anderson HA, and Selikoff IJ. Health status of workers with past exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in the manufacture of 2,4,5-trichlorophenoxyacetic acid: comparison of findings with and without chloracne. American J Industrial Medicine 1984; 5:161-182.

38. Suskind RR and Hertzberg VS. Human health effects of 2,4,5-T and its toxic contaminants. JAMA 1984; 2521:2372-2380.

39. May G. Tetrachlorodibenzodioxin: a survey of subjects ten years after exposure. Br J Indust Med 1982; 39:128-135.

40. Goldman PJ. Schwerste akute chloracne, eine massenintoxikation durch 2,3,6,7-tetrachlordibenzodioxin. Der Hautarzt 1973; 24:149-152.

41. Pazderova-Veljlupkova J, Nemcova M, Pickova J, Jirasek, L, and Lukas E. The development and prognosis of chronic intoxication by tetrachlorodibenzo-p-dioxin in men. Arch Environ Health 1981; 36:5-11.

42. Poland AP, Smith D, Metter G, and Possick P. A health survey of workers in a 2,4-D and 2,4,5-T plant with special attention to chloracne, porphyria cutanea tarda, and psychologic parameters. Arch Environ Health 1971; 22:316-327.

43. Bleiberg J, Wallen M, Brodkin R, and Applebaum IL. Industrially acquired porphyria. Archives of